New paper indicates a potential fifty-percent reduction in cardiac events for prostate cancer patients with pre-existing cardiovascular disease when treated with FIRMAGON® (degarelix) compared to LHRH agonists
inA paper published today in European Urology, the official journal of the European Association of Urology, indicates that the gonadotropin…